CoChat

Epithelial to Mesenchymal Transition: A Mechanism that Fuels Cancer Radio/Chemoresistance

Open access

The DOI matches its Crossref record; 136 of the 137 references it cites were found in a registry or an index.

Abstract

Epithelial to mesenchymal transition (EMT) contributes to tumor progression, cancer cell invasion, and therapy resistance. EMT is regulated by transcription factors such as the protein products of the SNAI gene family, which inhibits the expression of epithelial genes. Several signaling pathways, such as TGF-beta1, IL-6, Akt, and Erk1/2, trigger EMT responses. Besides regulatory transcription factors, RNA molecules without protein translation, micro RNAs, and long non-coding RNAs also assist in the initialization of the EMT gene cluster. A challenging novel aspect of EMT research is the investigation of the interplay between tumor microenvironments and EMT. Several microenvironmental factors, including fibroblasts and myofibroblasts, as well as inflammatory, immune, and endothelial cells, induce EMT in tumor cells. EMT tumor cells change their adverse microenvironment into a tumor friendly neighborhood, loaded with stromal regulatory T cells, exhausted CD8+ T cells, and M2 (protumor) macrophages. Several EMT inhibitory mechanisms are instrumental in reversing EMT or targeting EMT cells. Currently, these mechanisms are also significant for clinical use.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cells9020428

Cites

136 of 136 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.
Figure 1 Main EMT regulatory mechanisms. EMT is a product of internal and external events in cells. It is mainly induced by external factors, such as TGF-β1, neurotrophins, or interleukin-6, which activate several signaling pathways such as WNT, Smads, STATs, Akt, or Erk1/2. The activated pathways drive transcription factors (Goosecoid, Snail, Slug, Twist, nuclear factor erythroid-2-related factor 2 (NRF2), and Krüppel-like factors (KLFs)) to bind to special responding sequences in DNA, and, consequently, these mainly suppress the expression of genes related to epithelial differentiation. The best-known event in this process is the down-regulation of E-cadherin by the SNAI transcription factors, Snail, and Slug. At the same time, mesenchymal gene products, such as vimentin, are induced during the transcriptional changes in the EMT process, where the Smad, HIF-1α, and KLF4 transcription factors are directly involved [43,44]. The transcription regulatory process during EMT does not only rely on transcription factors, but also on long noncoding RNAs (lncRNAs) and microRNAs. The external EMT-inducing factors, such as TGF-β1, neurotrophins, or interleukin-6, are available from the fibroblastic and inflammatory microenvironment, but tumor cells also actively participate in the completion of an EMT program [45]. Based on the experimental data of several research groups, including ours, it has been found that acidic extracellular conditions and, in a further step, a low oxygen tension (hypoxia) are necessary for EMT. Interestingly, EMT tumor cells produce immune checkpoint regulatory molecules and actively remodel their immune microenvironment into a more tumor-friendly one from a hostile neighborhood.CC BY · PubMed Central
Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].
Figure 2 The TGF-β1 gradient causes heterogeneity in the tumor cell nests. There are higher TGF-β1 concentrations near the tumor vasculature, and the tumor cell nest has a decreasing gradient from its border towards the middle, which generates heterogeneity between the tumor–stroma interface and the tumor cell nest center [47]. The TGF-β1 gradient contributes to the heterogenic architecture of the tumor cell nest, where the invasive front has a completely different functional and differentiation profile than the core of the tumor cell nest. Additionally, at the invasive front, tumor cells interact with fibroblasts, leukocytes, and other stromal cells. Some scattered tumor cells undergo EMT at the tumor cell nest–stroma interface and contain both epithelial and mesenchymal markers. The figure is based on a figure published by Mayorca-Giuliani and Erler [48], which has been updated by the published data of Nieto et al. [29].CC BY · PubMed Central
Figure 3 Vimentin represents an extended fibroblastic component in a primary oral squamous cell carcinoma (OSCC). Tissue section of human OSCC with the detection of vimentin (magenta) and pan-cytokeratin (green) and cell nuclei counterstained with DAPI (blue). Tumor cells form nests with a decreasing representation of the epithelial differentiation marker pan-cytokeratin from the middle of the tumor cell nests to their border. Among the tumor cell nests, the stroma contains large amounts of vimentin+ fibroblasts. This image was taken by the TissueFaxsTM system (Tissuegnostics Vienna), and the bar represents 100 µm.
Figure 3 Vimentin represents an extended fibroblastic component in a primary oral squamous cell carcinoma (OSCC). Tissue section of human OSCC with the detection of vimentin (magenta) and pan-cytokeratin (green) and cell nuclei counterstained with DAPI (blue). Tumor cells form nests with a decreasing representation of the epithelial differentiation marker pan-cytokeratin from the middle of the tumor cell nests to their border. Among the tumor cell nests, the stroma contains large amounts of vimentin+ fibroblasts. This image was taken by the TissueFaxsTM system (Tissuegnostics Vienna), and the bar represents 100 µm.CC BY · PubMed Central
Figure 4 Multinuclear giant cells are therapy surviving intermediates. Hostile environmental conditions and hypoxia, in concert with EMT triggering factors, might induce EMT cells and polyploid giant cancer cells (PGCCs). These cells are also produced by serum-free culture conditions using conditioned media of oral squamous cell carcinoma cells and fibroblasts at pH = 6.7. These giant cells are also frequently the surviving cells of cultured OSCC cell lines during cisplatin or mitomycin C treatments. After the treatment cycles, the giant cells contribute to the expansion of the cell culture of normal epithelial tumor cell nests.
Figure 4 Multinuclear giant cells are therapy surviving intermediates. Hostile environmental conditions and hypoxia, in concert with EMT triggering factors, might induce EMT cells and polyploid giant cancer cells (PGCCs). These cells are also produced by serum-free culture conditions using conditioned media of oral squamous cell carcinoma cells and fibroblasts at pH = 6.7. These giant cells are also frequently the surviving cells of cultured OSCC cell lines during cisplatin or mitomycin C treatments. After the treatment cycles, the giant cells contribute to the expansion of the cell culture of normal epithelial tumor cell nests.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 136 references

Cited by

Metadata

Authors
Dudás, J., Ladányi, A., Ingruber, J., Steinbichler, T. B., & Riechelmann, H.
Affiliations
  • Innsbruck Medical University (AT)
  • National Institute of Oncology (HU)
Corresponding author
Dudás, József
Venue
Cells
Publisher
MDPI AG
Published
2020-02-12
Volume
9
Issue
2
Pages
428
ISSN
2073-4409 (ISSN-L)
OpenAlex
W3006507687
Cited by
213
References
137
Citations by year
2026: 21 · 2025: 31 · 2024: 41 · 2023: 34 · 2022: 40 · 2021: 28 · 2020: 16
FWCI
3.17
Type
journal article
Language
en
Open access
Locations
  • Cells (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Austrian Science Fund (P25869-B13, I3976-B33)
  • Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (ANN 128524)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
Keywords
epithelial-mesenchymal transition, cancer therapy resistance, radioresistance (biology), chemoresistance, TGF-β1 signaling, microRNA, long non-coding RNA, tumor microenvironment, cancer-associated fibroblasts, myofibroblasts, regulatory T cells, M2 macrophages, CD8+ T cell exhaustion, EMT reversal
MeSH terms
Antineoplastic Agents, Phytogenic, Humans, Neoplasms, Transcription Factors, Signal Transduction, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Mitogen-Activated Protein Kinase 3, T-Lymphocytes, Regulatory, Epithelial-Mesenchymal Transition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.